Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bamocaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals

Next Previous
Drug Profile

Bamocaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals

Alternative Names: Ivacaftor/bamocaftor/tezacaftor; Ivacaftor/tezacaftor/bamocaftor; Tezacaftor/ivacaftor/bamocaftor; Tezacaftor/VX-659/ivacaftor; VX-659/ivacaftor/VX-661; VX-659/TEZ/IVA; VX-659/VX-770/VX-661; VX659/ivacaftor/tezacaftor

Latest Information Update: 27 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Antifibrotics; Cyclopropanes; Fluorobenzenes; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 27 Aug 2024 Discontinued - Phase-II for Cystic fibrosis in Israel, Ireland, United Kingdom (PO), before August 2024 (Vertex Pharmaceuticals pipeline, August 2024)
  • 27 Aug 2024 Discontinued - Phase-III for Cystic fibrosis (In adolescents, In children, In the elderly, In adults) in USA, Australia, Canada, United Kingdom, Switzerland, Poland, Ireland, Israel, Israel, Spain, Denmark, Germany (PO), before August 2024 (Vertex Pharmaceuticals pipeline, August 2024)
  • 31 Dec 2021 Vertex Pharmaceuticals terminates a phase III trial in Cystic Fibrosis (In children, In adolescents, In adults, In the elderly) in USA, Ireland, Spain, Australia, Canada, Denmark, Germany, Israel, Poland, Switzerland and the United Kingdom (PO, Tablet) (NCT03447262)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top